Literature DB >> 9523748

Management of chronic immune thrombocytopenic purpura in children and adults.

V Blanchette1, J Freedman, B Garvey.   

Abstract

Chronic immune thrombocytopenic purpura (ITP) is characterized by macrophage destruction of platelets, primarily in the spleen, and occurs in both adults and children. Historically, splenectomy is often required, especially in adults with chronic ITP; however, several medical options have been used successfully prior to splenectomy or when this procedure has either failed or been refused by the patient. These include corticosteroids, intravenous immunoglobulin (IVIg), intravenous anti-D, danazol, vinca alkaloids, and other immunosuppressive agents such as azathioprine and cyclophosphamide. Platelet transfusions have been used in emergency situations. Several therapies that have been reported, but that are rarely used in chronic ITP, include cyclosporine A, interferon-alpha (IFN-alpha), plasma exchange, staphylococcal protein A immunoadsorption, combination chemotherapy, dapsone, ascorbic acid, and colchicine. Each of these approaches to treatment of chronic ITP are discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9523748

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  3 in total

Review 1.  Treatment of immune thrombocytopenic purpura in children : current concepts.

Authors:  Aziza T Shad; Corina E Gonzalez; S G Sandler
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

2.  Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006-2012.

Authors:  Ruopeng An; Peizhong Peter Wang
Journal:  Vasc Health Risk Manag       Date:  2017-01-20

3.  The clinical effect of Prednisone in combination with Mycophenolate mofetil on idiopathic thrombocytopenic purpura (ITP) and its influence on the level of peripheral blood T lymphocytes and NK lymphocytes.

Authors:  Jiangwei Xu; Gangzuo Wang; Sihai Tan; Yirong Ge; Jingzhen Liu; Mei Rao; Yufeng Deng
Journal:  Saudi J Biol Sci       Date:  2019-09-12       Impact factor: 4.219

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.